SHELTON CAPITAL MANAGEMENT - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.

Quarter-by-quarter ownership
SHELTON CAPITAL MANAGEMENT ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q4 2022$3,042,653
-64.7%
74,850
-43.2%
0.32%
-22.2%
Q3 2022$8,616,000
-5.5%
131,850
-12.1%
0.41%0.0%
Q2 2022$9,116,000
-3.2%
150,0000.0%0.41%
+17.8%
Q1 2022$9,416,000
-17.2%
150,0000.0%0.35%
-13.4%
Q4 2021$11,367,000
-16.8%
150,000
+23.0%
0.40%
-24.7%
Q3 2021$13,655,000
-4.1%
122,000
+38.6%
0.53%
-0.7%
Q2 2021$14,246,000
+46.1%
88,000
+10.0%
0.54%
+58.7%
Q1 2021$9,748,000
+70.7%
80,000
+114.5%
0.34%
+31.9%
Q4 2020$5,711,000
+113.4%
37,300
+16.6%
0.26%
+131.5%
Q3 2020$2,676,000
+13.8%
32,0000.0%0.11%
-14.6%
Q2 2020$2,352,000
+73.3%
32,0000.0%0.13%
+32.7%
Q1 2020$1,357,000
-3.1%
32,000
+39.1%
0.10%
+27.3%
Q4 2019$1,401,000
+55.3%
23,000
+4.5%
0.08%
+45.3%
Q3 2019$902,000
-12.9%
22,0000.0%0.05%
-11.7%
Q2 2019$1,036,000
-94.0%
22,000
+3459.9%
0.06%
-11.8%
Q1 2019$17,300,000
+4626.8%
618
-95.2%
0.07%
+172.0%
Q4 2018$366,000
+9.9%
12,800
+70.7%
0.02%
+31.6%
Q3 2018$333,000
-24.5%
7,5000.0%0.02%
-29.6%
Q2 2018$441,0007,5000.03%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q2 2020
NameSharesValueWeighting ↓
Versant Venture Management, LLC 508,558$82,330,00027.28%
Valiant Capital Management, L.P. 307,700$49,814,0003.74%
NEA Management Company, LLC 1,590,002$257,405,0003.35%
NIA IMPACT ADVISORS, LLC 39,891$6,458,0003.15%
Ikarian Capital, LLC 200,000$32,379,0002.62%
Soleus Capital Management, L.P. 103,114$16,693,0002.57%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 157,334$25,471,0002.47%
Capital Impact Advisors, LLC 45,440$7,356,0002.37%
ARK Investment Management 7,776,119$1,258,876,0002.34%
Sassicaia Capital Advisers LLC 13,513$2,188,0002.28%
View complete list of CRISPR THERAPEUTICS AG shareholders